

Lipum's ongoing clinical phase 1 study proceeds as planned

Lipum AB (publ) announces that the clinical phase 1 study with the drug candidate SOL-116 is proceeding as planned. After a fourth dose escalation, a safety evaluation has now been conducted and as expected, data show that SOL-116 remains safe and well tolerated. The study is therefore continuing as planned with a higher dose level for the fifth group. SOL-116 is being developed for the treatment of chronic inflammatory diseases.

The study is designed as a double-blind, randomized and placebo controlled FIH (First In Human) study and includes up to six dose groups of healthy subjects. In addition, a group of patients diagnosed with rheumatoid arthritis will participate in the study.

"The study proceeds very well, and we are on schedule. We are also approaching the stage where a group of patients can be included, which provides the opportunity to study any differences between healthy subjects and patients with rheumatoid arthritis and provide guidance in the design of subsequent studies.", says Einar Pontén, CEO of Lipum.

The primary objective of the study is to establish safety and tolerability of SOL-116, and the secondary objective is to study its pharmacokinetics. The study is a dose escalation study, and each subject receives only one dose of SOL-116 (Single Ascending Dose, SAD). After safety evaluation of a whole group, the dose is gradually increased for each new group included in the study.

Contacts

Einar Pontén, CEO

E-post: einar.ponten@lipum.se

Mobile: +46 70 578 34 95

Web: www.lipum.se

About Us

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

PRESS RELEASE

23 March 2023 16:50:00 CET



Attachments

[Lipum's ongoing clinical phase 1 study proceeds as planned](#)